EUCTR2007-001938-14-IT进行中（未招募）不适用
eoadjuvant docetaxel, cisplatin and 5-fluororacil (TPF) followed by radiotherapy plus concomitant chemotherapy or cetuximab versus radiotherapy plus concomitant chemotherapy or cetuximab in patients with locally advanced squamous cell carcinoma of the head and neck. A randomized phase III factorial study - HN07
AVAPO RICERCHE - VENEZIA0 个研究点开始时间: 2008年5月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically or cytologically proven squamous cell carcinoma of the head and neck. 2. Primary tumor sites eligible : oral cavity, oropharynx, hypopharynx Although they are admittedly of squamous cell types, the following tumors will be excluded because of them responsiveness to chemotherapy: tumors of the nasal and paranasal cavities and of the nasopharynx.3. Stage 3 or 4 disease without evidence of distant metastases verified by chest X?Ray, abdominal ultrasound, or CT (liver function test abnormalities); bone scan in case of local symptoms.4. At least one uni or bidimensionally measurable lesion.5. Tumor considered inoperable after evaluation by a multidisciplinary team (i.e. a surgeon, a medical oncologist and a radiation oncologist). Criteria for inoperability are: a) technical unresectability: tumor fixation/invasion to base of the skull or cervical vertebrae, involvement of the nasopharynx, and fixed lymph nodes.b) Physician decision based on low surgical curability. This category will include the following: i) All T3-4 stages.ii) All N2-3 stages excluding T1 N2.iii) Patients for organ preservation. Reason for inoperability will be recorded in the CRF.6. No previous chemotherapy or radiotherapy for any reason and no previous surgery for SCCHN (other than biopsy) are allowed at time of study entry. 7. Age > 18 years.8. Karnofsky performance status > 70. (ECOG 0-1) (Appendix II)9. No active alcohol addiction.10. Life expectancy > 6 months.11. Signed informed consent prior to beginning protocol specific procedures.12. Adequate bone marrow, hepatic and renal functions as evidenced by the following:a) Hematology (Bone marrow):i) Neutrophils > 2.0 109/Lii) Platelets > 100 x 109/Liii) Hemoglobin > 10 g/dLb) Hepatic functioni) Total bilirubin < 1 x UNLii) ASAT (SGOT) and ALAT (SGPT) < 2.5 x ULNiii) Alkaline phosphatase < 5 x ULN Patients with ASAT or ALAT > 1.5 x ULN associated with alkaline phosphatase > 2.5 x ULN are not eligible for the study.c) Renal function : serum creatinine < 1 x UNL. In case of borderline value the creatinine clearance > 60 ml/min (calculated by the Cockcroft-Gault method) . 13. Patients must be available for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating center.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnant or lactating women or women of childbearing potential not using adequate contraception.2. Previous or current malignancies at other sites, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma of the skin, or other cancer curatively treated by surgery and with no evidence of disease for at least 5 years. Any prior treatment with radiotherapy or chemotherapy is an exclusion criterion.3. Symptomatic peripheral neuropathy > grade 2 by NCIC-CTG criteria4. Symptomatic altered hearing > grade 2 by NCIC-CTG criteria.5. Other serious illnesses or medical conditions including:a) Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry.b) History of significant neurologic or psychiatric disorders including dementia or seizures.c) Active uncontrolled infection.d) Active peptic ulcer.e) Hypercalcemia.f) Chronic obstructive pulmonary disease requiring hospitalization during the year preceding study entry6. History of ipersensitivity reaction to polysorbate 80 (Appendix IV)7. Patients requiring intravenous alimentation.8. Patients who experienced a weight loss of more than 20% of their body weight in the 3 months preceding study entry.9. Concomitant treatment with any other anticancer therapy.10. Participation in a therapeutic clinical trial within 30 days of study entry
研究者
相似试验
招募中
2 期
eoadjuvant capecitabine, oxaliplatin, docetaxel and atezolizumab in non-metastatic, resectable gastric and GE-junction cancer. ;The PANDA trialgastric cancerstomach cancer10017990NL-OMON50269ederlands Kanker Instituut20
招募中
2 期
Pre-operative capecitabine, oxaliplatin, docetaxel and atezolizumab in gastric cancer (PANDA)2024-519075-26-00Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting21
进行中（未招募）
1 期
A Phase II Trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic carcinoma of the penis - Penile TPFocally advanced and metastatic carcinoma of the penisMedDRA version: 13.1Level: LLTClassification code 10034299Term: Penile cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000707-28-GBThe Institute of Cancer Research29
已完成
3 期
Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and NeckHead and Neck Squamous Cell CarcinomaNCT01086826Associazione Volontari Pazienti Oncologici320
进行中（未招募）
1 期
eoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer - EXPRESSIOEligible will be only females between 18 - 70 years of age, suffering from histologically confirmed primary breast cancer, nodal status positive or negative, phase cT2, cT3, or cT4 including inflammatory disease. Metastatic disease is excluded. All patients will be treated with 3 cycles Docetaxel and 3 cycles FEC.MedDRA version: 14.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-006381-29-DEniversitätsmedizin Mainz200